Fujifilm Diosynth Biotechnologies extended its gene therapy and viral vaccine fill/finish capabilities to provide services in support of late-phase candidates and commercial supply. Fujifilm has invested in Vanrx Pharmasystems’ SA25 Aseptic Filling Workcell gloveless isolator technology with automated environmental monitoring and no glass-to-glass contact.  

Fujifilm’s fill/finish services offer rapid changeover between drug products and containers, production predictability, and the ability to scale up to support commercial production, according to Gerry Farrell, COO of Fujifilm’s Texas site.

“Developers of advanced therapies need to be ready to move swiftly into commercial production, from bulk drug substance and into final dosage form,” said Farrell. “We recognized that having fill/finish capabilities that extend beyond the current clinical stage is essential to support the rapid delivery of clinical candidates to patients.” 

Previous articleOptimize, Adapt, and Overcome: Tips from the Cell Line Development Front
Next articleDesigning Immune Tissues to Create Next-Generation Vaccines and Immunotherapies